	US 12,227,590 B2
	*Methods and composition for a binding molecule targeting cancer cells expressing SSX2 peptide 41-49 in HLA-A0201 context**
Eric Yvon, Bethesda, MD (US); Catherine Bollard, Bethesda, MD (US); Stacey Van Pelt, Houston, TX (US); Scott Raskin, Silver Spring, MD (US); Gerhard Held, Homburg (DE); Christine Sturm, Homburg (DE); and Michael Pfreundschuh, deseased, Homburg (DE)
Assigned to CHILDREN'S NATIONAL MEDICAL CENTER; THE GEORGE WASHINGTON UNIVERSITY; and UNIVERSITAT DES SAARLANDES, Saarbrucken (DE)
Filed by Astrid Tschiersch-Pfrelindschuh; CHILDREN'S NATIONAL MEDICAL CENTER, Washington, DC (US); THE GEORGE WASHINGTON UNIVERSITY, Washington, DC (US); and UNIVERSITAT DES SAARLANDES, Saarbrücken (DE)
Filed on Dec. 16, 2021, as Appl. No. 17/552,862.
Application 17/552,862 is a continuation of application No. PCT/US2020/038958, filed on Jun. 22, 2020.
Claims priority of provisional application 62/864,957, filed on Jun. 21, 2019.
Prior Publication US 2022/0185909 A1, Jun. 16, 2022
Int. Cl. C07K 16/30 (2006.01); A61K 39/00 (2006.01); C07K 14/47 (2006.01)

CPC C07K 16/30 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464484 (2023.05); C07K 14/4703 (2013.01); A61K 2239/48 (2023.05); C07K 2317/34 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01)]

7 Claims

1. A Synovial Sarcoma X breakpoint 2 (SSX2) binding molecule comprising:

(i) 3 complementarity determining regions (CDRs) from the light chain variable region, wherein

the first CDR comprises the sequence set forth in SEQ ID NO: 1,

the second CDR comprises the sequence set forth in SEQ ID NO: 2, and

the third CDR comprises the sequence set forth in SEQ ID NO: 3; and

(ii) 3 CDRs from the heavy chain variable region, wherein

the first CDR comprises the sequence set forth in SEQ ID NO: 4,

the second CDR comprises the sequence set forth in SEQ ID NO: 5, and

the third CDR comprises the sequence set forth in SEQ ID NO: 6;

wherein the binding molecule targets a SSX2 peptide 41-49 (SEQ ID NO:07).